Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1909 1
1913 3
1916 2
1917 1
1919 1
1922 1
1925 1
1927 1
1928 2
1932 4
1933 2
1934 5
1935 8
1936 11
1937 13
1938 8
1939 5
1940 1
1941 1
1942 2
1944 3
1945 1
1946 4
1947 3
1949 1
1950 3
1952 2
1954 4
1955 3
1956 6
1957 2
1959 1
1960 1
1961 2
1962 2
1963 1
1964 2
1965 2
1966 2
1967 1
1968 2
1969 1
1971 1
1972 6
1973 2
1974 4
1975 5
1976 3
1977 7
1978 3
1979 4
1980 6
1981 8
1982 4
1983 13
1984 11
1985 14
1986 11
1987 11
1988 12
1989 19
1990 18
1991 17
1992 20
1993 18
1994 19
1995 25
1996 27
1997 18
1998 24
1999 20
2000 19
2001 27
2002 23
2003 17
2004 30
2005 32
2006 31
2007 31
2008 39
2009 27
2010 40
2011 38
2012 48
2013 38
2014 59
2015 76
2016 92
2017 81
2018 97
2019 74
2020 121
2021 153
2022 152
2023 170
2024 78
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,879 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. Among authors: gordon li. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. J Natl Compr Canc Netw. 2021. PMID: 34781267
Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new …
Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as …
Validation of a decision regret scale.
Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D. Brehaut JC, et al. Among authors: gordon e. Med Decis Making. 2003 Jul-Aug;23(4):281-92. doi: 10.1177/0272989X03256005. Med Decis Making. 2003. PMID: 12926578
RESULTS: The scale showed good internal consistency (Cronbach's alpha = 0.81 to 0.92). It correlated strongly with decision satisfaction (r = -0.40 to -0.60), decisional conflict (r = 0.31 to 0.52), and overall rated quality of life (r = -0.25 to -0.27). ...
RESULTS: The scale showed good internal consistency (Cronbach's alpha = 0.81 to 0.92). It correlated strongly with decision satisfaction ( …
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong WP, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. Corbett KS, et al. Among authors: gordon i. N Engl J Med. 2020 Oct 15;383(16):1544-1555. doi: 10.1056/NEJMoa2024671. Epub 2020 Jul 28. N Engl J Med. 2020. PMID: 32722908 Free PMC article.
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, Pichet Binette A, Palmqvist S, Sato C, Sachdev P, Koyama A, Gordon BA, Benzinger TLS, Holtzman DM, Morris JC, Mattsson-Carlgren N, Stomrud E, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Horie K, et al. Among authors: gordon ba. Nat Med. 2023 Aug;29(8):1954-1963. doi: 10.1038/s41591-023-02443-z. Epub 2023 Jul 13. Nat Med. 2023. PMID: 37443334 Free PMC article.
In combination with p-tau205, MTBR-tau243 explained most of the total variance in tau-PET burden (0.58 R(2) 0.75) and the performance in predicting cognitive measures (0.34 R(2) 0.48) approached that of tau-PET (0.44 R(2) 0.52). ...
In combination with p-tau205, MTBR-tau243 explained most of the total variance in tau-PET burden (0.58 R(2) 0.75) and the performance …
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T. Abramson JS, et al. Among authors: gordon li. Blood. 2024 Feb 1;143(5):404-416. doi: 10.1182/blood.2023020854. Blood. 2024. PMID: 37890149
Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001 study. ...Liso-cel demonstrat …
Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for …
ALSFRS-R.
Gordon PH, Miller RG, Moore DH. Gordon PH, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:90-3. doi: 10.1080/17434470410019906. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512883 Review.
The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimizes dropout, reduces cost, and correlates with survival. Unlike the other standard outcome measures currently employed, the ALSFRS-R is …
The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimize …
Inference-Based Quantum Sensing.
Huerta Alderete C, Gordon MH, Sauvage F, Sone A, Sornborger AT, Coles PJ, Cerezo M. Huerta Alderete C, et al. Among authors: gordon mh. Phys Rev Lett. 2022 Nov 4;129(19):190501. doi: 10.1103/PhysRevLett.129.190501. Phys Rev Lett. 2022. PMID: 36399750
The success of this task hinges on the ability to correlate changes in the parameter to changes in the system response R(teta) (i.e., changes in the measurement outcomes). For simple cases the form of R(teta) is known, but the same cannot be said for realistic scena …
The success of this task hinges on the ability to correlate changes in the parameter to changes in the system response R(teta) (i.e., …
Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).
Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, Francis J, Speroff T, Gautam S, Margolin R, Sessler CN, Dittus RS, Bernard GR. Ely EW, et al. Among authors: gordon s. JAMA. 2003 Jun 11;289(22):2983-91. doi: 10.1001/jama.289.22.2983. JAMA. 2003. PMID: 12799407
In addition, 5 methods were used to test the construct validity of the RASS, including correlation with an attention screening examination (r = 0.78, P<.001), GCS scores (r = 0.91, P<.001), quantity of different psychoactive medication dosages 8 hours prior to …
In addition, 5 methods were used to test the construct validity of the RASS, including correlation with an attention screening examination ( …
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
Morenas-Rodríguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suárez-Calvet M, Fagan AM, Schultz S, Gordon BA, Benzinger TLS, Hassenstab J, McDade E, Feederle R, Karch CM, Schlepckow K, Morris JC, Kleinberger G, Nellgard B, Vöglein J, Blennow K, Zetterberg H, Ewers M, Jucker M, Levin J, Bateman RJ, Haass C; Dominantly Inherited Alzheimer Network. Morenas-Rodríguez E, et al. Among authors: gordon ba. Lancet Neurol. 2022 Apr;21(4):329-341. doi: 10.1016/S1474-4422(22)00027-8. Lancet Neurol. 2022. PMID: 35305339 Free PMC article.
Augmented annual rates of increase in soluble TREM2 were associated with a diminished rate of decrease in amyloid deposition, as measured by Abeta42 in CSF (r=0.56 [0.22], p=0.011), in presymptomatic carriers of pathogenic variants, and with diminished annual rate of incre …
Augmented annual rates of increase in soluble TREM2 were associated with a diminished rate of decrease in amyloid deposition, as measured by …
Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction.
Scandalis L, Kitzman DW, Nicklas BJ, Lyles M, Brubaker P, Nelson MB, Gordon M, Stone J, Bergstrom J, Neufer PD, Gnaiger E, Molina AJA. Scandalis L, et al. Among authors: gordon m. JAMA Cardiol. 2023 Jun 1;8(6):575-584. doi: 10.1001/jamacardio.2023.0957. JAMA Cardiol. 2023. PMID: 37163294 Free PMC article.
Maximal capacity was strongly and significantly correlated with peak exercise oxygen consumption (R = 0.69; P < .001), 6-minute walk distance (R = 0.70; P < .001), and Short Physical Performance Battery score (R = 0.46; P < .001). ...

Maximal capacity was strongly and significantly correlated with peak exercise oxygen consumption (R = 0.69; P < .001), 6-minute wa

…
1,879 results